Vanguard Fiduciary Trust
CORT icon

Vanguard Fiduciary Trust’s Corcept Therapeutics CORT Stock Holding History

Vanguard Fiduciary Trust’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$53.4M Buy
614,078
+23,771
+4% +$1.44M 0.01% 829
2026
Q1 		$23.8M Buy
+590,307
New +$22.1M 0.01% 1224

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust's CORT Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Corcept Therapeutics (CORT) stake by 4% in Q2 2026, buying an estimated $1.44M and bringing the position to 614,078 shares worth $53.4M. The position accounts for 0.01% of the portfolio, ranked #829.

Vanguard Fiduciary Trust first reported a position in CORT in Q1 2026 and has held it in 2 quarters since. 420 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Vanguard Fiduciary Trust held 614,078 shares of Corcept Therapeutics worth $53.4M as of Q2 2026.
  • Vanguard Fiduciary Trust bought 23,771 Corcept Therapeutics shares in Q2 2026, an estimated $1.44M.
  • Corcept Therapeutics made up 0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #829 holding.
  • Vanguard Fiduciary Trust first reported a position in Corcept Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 420 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.